NCT06381466 - A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

September 16, 2025

Study Completion Date

September 16, 2025

Conditions

Dilated Cardiomyopathy

Interventions

DRUG

AZD0233

Randomized participants will receive AZD0233 orally as a single ascending dose (dose 1, dose 2, dose 3, dose 4 or dose 5) or multiple ascending dose (dose 6, dose 7 or dose 8)

DRUG

AZD0233 Placebo

Randomized participants will receive matching placebo orally as a SAD or MAD.

Trial Locations (1)

91206

Research Site, Glendale